Rasio cepet Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc. (BEAM) relies on a unique patent perimeter for precision genome editing. The current ratio demonstrates present solvency, with the latest value recorded as 14.62. The company's financial status depends on external capital, as it lacks commercial products. The business is currently scaling clinical trials and expanding its own production capacities to implement point DNA modifications.

Assessing the fundamental risks of Beam Therapeutics Inc. (BEAM) requires an analysis of the company's ability to cover short-term obligations excluding slow-moving inventories. The current quick ratio of 14.62 reflects the volume of liquid assets and accounts receivable necessary to fund costly developments in precision DNA base editing without the urgent need to raise external capital.